SPPI – Zevalin shows benefit in treatment of aggressive lymphoma

SPPI announced results this morning for a ramdomised study. The study compared outcomes for a small group f patients (n=43) with aggressive lymphoma who were treated with Zevalin & high dose chemotherapy (Z-BEAM) vs. high dose chemotherapy alone (BEAM). Both groups also had autologous stem-cell transplantation (ASCT). Two Year Overall Survival Rate Was 91% for Z-BEAM vs. 62% for BEAM Alone. The company is expanding its clinical development program for Zevalin to reflect this finding – and will support a larger study to help understand potential benefit of Zevalin in this setting.

SPPI opened up ~4% on the news.

Here’s a link to the abstract:


DSCO also opened well today – it has been as high as $2.25 this morning so far. It appears that I sold right at its recent nadir. Oh well.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s